Cape Town-based research group Biovac has announced a major technology transfer agreement with Indian pharmaceutical firm Biological E, reported Business Day (27 July 2025).
“The vaccine, PCV14, is already licensed in India and is currently undergoing the World Health Organisation (WHO) prequalification process.
“The deal will enable Biovac to produce and distribute a pneumococcal conjugate vaccine (PCV14) across Africa, reducing the continent’s heavy reliance on imports and funding. “Currently, Africa produces 1% of the vaccines it consumes, a figure the Africa Centres for Disease Control and Prevention (Africa CDC) aims to increase to 60% by 2040.”